(firstQuint)Study of Mycamine in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug.

 This is a prospective, multicenter, open-label, repeat-dose study.

 Subjects will receive treatment with intravenous micafungin for 10 to 14 days (per investigator clinical judgment) at a daily dose of 4.

5 mg/kg (determined by the subject's weight at baseline).

 Serial blood samples for assessment of pharmacokinetics will be collected.

.

 Study of Mycamine in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug@highlight

Infants and toddlers with fungal infections will receive 10 to 14 days of treatment with an antifungal drug.

 Safety and drug blood levels will be assessed